PT  - JOURNAL ARTICLE
AU  - Jasmine N Khouja
AU  - Eleanor Sanderson
AU  - Robyn E Wootton
AU  - Amy E Taylor
AU  - Marcus R Munafò
TI  - A multivariable Mendelian randomisation study exploring the direct effects of nicotine on health compared with the other constituents of tobacco smoke: Implications for e-cigarette use
AID  - 10.1101/2021.01.12.21249493
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.12.21249493
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249493.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249493.full
AB  - Objectives Given the popularity of e-cigarettes, and the lack of longitudinal evidence regarding their safety, novel methods are required to explore potential health effects resulting directly from nicotine use. The aim of this study was to explore the direct effects of nicotine compared with the other constituents of tobacco smoke on health outcomes associated with smoking.Design Observational study, using Mendelian randomisation and multivariable Mendelian randomisation analyses of summary data.Setting Summary data from two previous genome-wide association studies, and summary data generated from UK Biobank, a prospective cohort study.Participants N = 337,010 individuals enrolled in UK Biobank, and a total of N = 341,882 individuals from two previous genome-wide association studies.Main outcome measures We explored the effect of cotinine levels (as a proxy for nicotine exposure) and smoking heaviness (to capture cigarette smoke exposure) on body mass index (BMI), chronic obstructive pulmonary disease (COPD), forced vital capacity (FVC), forced expiratory volume (FEV-1), coronary heart disease (CHD), and heart rate.Results In multivariable Mendelian randomisation analyses, there was weak evidence to suggest that increased cotinine levels may cause increased heart rate among current smokers (β = 0.50 bpm, 95% CI −0.06 to 1.05). There was stronger evidence to suggest that increased smoking heaviness causes decreased BMI among current smokers (β = −1.81 kg/m2, 95% CI −2.64 to −0.98), as well as increased risk of COPD, decreased FEV-1 and FVC, and increased heart rate among ever and current smokers. We also found evidence to suggest that increased smoking heaviness causes increased risk of CHD among ever smokers.Conclusions Our combined findings are consistent with smoking-related health outcomes being caused by exposure to the non-nicotine components of tobacco smoke.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Centre Integrative Epidemiology Unit at the University of Bristol [grant number MC_UU_00011/1, MC_UU_00011/7]. This research was also supported by the NIHR Bristol Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. REW is supported by a postdoctoral fellowship from the South-Eastern Regional Health Authority (2020024). This publication is the work of the authors and JNK, ES, REW, AET and MRM who had full access to all of the data (including statistical reports and tables) and will serve as guarantors for the contents of this paper. The authors take responsibility for the integrity of the data and the accuracy of the data analysis. The funder played no role in the design of the study, the data collection, data analysis, interpretation of data, in the writing of the report, or in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was sought from the UK Biobank (project 9142). UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC). The REC reference for UK Biobank is 11/NW/0382. Further details about the ethics approval sought for data collection in UK Biobank can be found online (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data is available at www.ukbiobank.ac.uk. GSCAN data is available at https://doi.org/10.13020/3b1n-ff32. The Cotinine Consortium data is available at https://doi.org/10.5523/bris.182rhz19hg3lz1172a7yfcap9v. https://www.ukbiobank.ac.uk/ https://doi.org/10.13020/3b1n-ff32 https://doi.org/10.5523/bris.182rhz19hg3lz1172a7yfcap9v